Synapse

← Antônio Waldo Zuardi

Papers by Antônio Waldo Zuardi

Page 2 · newest first

  1. Cannabidiol Is a Potential Therapeutic for the Affective-Motivational Dimension of Incision Pain in RatsFrontiers in Pharmacology · 2017
  2. Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real LifeFrontiers in Pharmacology · 2017
  3. Protective Effects of Cannabidiol against Seizures and Neuronal Death in a Rat Model of Mesial Temporal Lobe EpilepsyFrontiers in Pharmacology · 2017
  4. Basic features of generalized anxiety disorderMedicina (Ribeirão Preto) · 2017
  5. Early interventions for the prevention of PTSD in adults: a systematic literature reviewArchives of Clinical Psychiatry (São Paulo) · 2017
  6. A Conversion of Oral Cannabidiol to Delta9-Tetrahydrocannabinol Seems Not to Occur in HumansCannabis and Cannabinoid Research · 2017
  7. Even High Doses of Oral Cannabidiol Do Not Cause THC-Like Effects in Humans: Comment on Merrick et al. Cannabis and Cannabinoid Research 2016;1(1):102–112; DOI: 10.1089/can.2015.0004Cannabis and Cannabinoid Research · 2017
  8. Δ9-THC Intoxication by Cannabidiol-Enriched Cannabis Extract in Two Children with Refractory Epilepsy: Full Remission after Switching to Purified CannabidiolFrontiers in Pharmacology · 2016
  9. Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in RatsFrontiers in Pharmacology · 2016
  10. Cannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia PharmacotherapyFrontiers in Pharmacology · 2016
  11. Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic EffectsSHILAP Revista de lepidopterología · 2016
  12. Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 yearsTherapeutic Advances in Psychopharmacology · 2016
  13. Patterns of regional gray matter loss at different stages of schizophrenia: A multisite, cross-sectional VBM study in first-episode and chronic illnessNeuroImage Clinical · 2016
  14. Cannabidiol and Sodium Nitroprusside: Two Novel Neuromodulatory Pharmacological Interventions to Treat and Prevent PsychosisCNS & Neurological Disorders - Drug Targets · 2015
  15. Caffeine protects against memory loss induced by high and non-anxiolytic dose of cannabidiol in adult zebrafish (Danio rerio)Pharmacology Biochemistry and Behavior · 2015
  16. Δ-Tetrahydrocannabinol alone and combined with cannabidiol mitigate fear memory through reconsolidation disruptionEuropean Neuropsychopharmacology · 2015
  17. Evaluation of the role of the cannabidiol system in an animal model of ischemia/reperfusion kidney injuryRevista Brasileira de Terapia Intensiva · 2015
  18. Evaluation of Serum Cytokines Levels and the Role of Cannabidiol Treatment in Animal Model of AsthmaMediators of Inflammation · 2015
  19. Phytocannabinoids and epilepsyJournal of Clinical Pharmacy and Therapeutics · 2014
  20. Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trialJournal of Psychopharmacology · 2014
  21. Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis sativaCNS & Neurological Disorders - Drug Targets · 2014
  22. Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case seriesJournal of Clinical Pharmacy and Therapeutics · 2014
  23. Neuroimaging Studies of Acute Effects of THC and CBD in Humans and Animals: a Systematic ReviewCurrent Pharmaceutical Design · 2014
  24. Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strainFrontiers in Pharmacology · 2014
  25. Rimonabant effects on anxiety induced by simulated public speaking in healthy humans: a preliminary reportHuman Psychopharmacology Clinical and Experimental · 2013
  26. Acute and chronic administration of cannabidiol increases mitochondrial complex and creatine kinase activity in the rat brainBrazilian Journal of Psychiatry · 2013
  27. Human experimental anxiety: actual public speaking induces more intense physiological responses than simulated public speakingBrazilian Journal of Psychiatry · 2013
  28. Rapid Improvement of Acute Schizophrenia Symptoms After Intravenous Sodium NitroprussideJAMA Psychiatry · 2013
  29. Effects of acute systemic administration of cannabidiol on sleep-wake cycle in ratsJournal of Psychopharmacology · 2013
  30. Marijuana, feijoada and the debate on drug legalizationFrontiers in Psychiatry · 2013
  31. Cannabidiol for the treatment of cannabis withdrawal syndrome: a case reportJournal of Clinical Pharmacy and Therapeutics · 2012
  32. Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ⁹-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteersPsychological Medicine · 2012
  33. A Critical Review of the Antipsychotic Effects of Cannabidiol: 30 Years of a Translational InvestigationCurrent Pharmaceutical Design · 2012
  34. Antipsychotic Profile of Cannabidiol and Rimonabant in an Animal Model of Emotional Context Processing in SchizophreniaCurrent Pharmaceutical Design · 2012
  35. Oxytocin interference in the effects induced by inhalation of 7.5% CO₂ in healthy volunteersHuman Psychopharmacology Clinical and Experimental · 2012
  36. Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drugBrazilian Journal of Psychiatry · 2012
  37. Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drugBrazilian Journal of Psychiatry · 2012
  38. Pharmacological interventions in the treatment of the acute effects of cannabis: a systematic review of literatureHarm Reduction Journal · 2012
  39. Administration of Harmine and Imipramine Alters Creatine Kinase and Mitochondrial Respiratory Chain Activities in the Rat BrainDepression Research and Treatment · 2011
  40. Safety and Side Effects of Cannabidiol, a Cannabis sativa ConstituentCurrent Drug Safety · 2011
  41. COOP/WONCA Charts as a Screen for Mental Disorders in Primary CareThe Annals of Family Medicine · 2011
  42. Administration of cannabidiol and imipramine induces antidepressant-like effects in the forced swimming test and increases brain-derived neurotrophic factor levels in the rat amygdalaActa Neuropsychiatrica · 2011
  43. Anxiolytic-like effect of oxytocin in the simulated public speaking testJournal of Psychopharmacology · 2011
  44. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary reportJournal of Psychopharmacology · 2010
  45. The Fast Alcohol Screening Test (FAST) is as Good as the AUDIT to Screen Alcohol Use DisordersSubstance Use & Misuse · 2010
  46. Is the Full Version of the AUDIT Really Necessary? Study of the Validity and Internal Construct of Its Abbreviated VersionsAlcoholism Clinical and Experimental Research · 2010
  47. Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD)Brazilian Journal of Psychiatry · 2010
  48. Harmine and Imipramine Promote Antioxidant Activities in Prefrontal Cortex and HippocampusOxidative Medicine and Cellular Longevity · 2010
  49. Short admission in an emergency psychiatry unit can prevent prolonged lengths of stay in a psychiatric institutionBrazilian Journal of Psychiatry · 2009
  50. Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of maniaJournal of Psychopharmacology · 2009